Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval.
Brand Name : Bilaxten
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 20, 2021
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : Norgine
Deal Size : Undisclosed
Deal Type : Agreement
Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU
Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 12, 2020
Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : Norgine
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
